Design Therapeutics, Inc.
DSGN
$4.72
-$0.24-4.84%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 12.16M | 11.88M | 1.59M | 9.80M | 11.01M |
| Gross Profit | -12.16M | -11.88M | -1.59M | -9.80M | -11.01M |
| SG&A Expenses | 4.54M | 4.37M | 4.53M | 4.60M | 4.11M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.69M | 16.25M | 15.04M | 14.40M | 15.12M |
| Operating Income | -16.69M | -16.25M | -15.04M | -14.40M | -15.12M |
| Income Before Tax | -13.65M | -13.04M | -11.79M | -11.11M | -11.84M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -13.65M | -13.04M | -11.79M | -11.11M | -11.84M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -13.65M | -13.04M | -11.79M | -11.11M | -11.84M |
| EBIT | -16.69M | -16.25M | -15.04M | -14.40M | -15.12M |
| EBITDA | -16.55M | -16.09M | -14.89M | -14.26M | -14.98M |
| EPS Basic | -0.24 | -0.23 | -0.21 | -0.20 | -0.21 |
| Normalized Basic EPS | -0.15 | -0.14 | -0.13 | -0.12 | -0.13 |
| EPS Diluted | -0.24 | -0.23 | -0.21 | -0.20 | -0.21 |
| Normalized Diluted EPS | -0.15 | -0.14 | -0.13 | -0.12 | -0.13 |
| Average Basic Shares Outstanding | 56.68M | 56.62M | 56.56M | 56.49M | 56.09M |
| Average Diluted Shares Outstanding | 56.68M | 56.62M | 56.56M | 56.49M | 56.09M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
